In short
This article discusses a phase II clinical trial investigating the use of Gallium (68Ga) Tezatabep Matraxetan, also known as [68Ga]Ga-ABY-025, in PET imaging for evaluating HER2 status in patients with gastro-esophageal and HER2-low breast cancer. The study aims to assess the effectiveness of this non-invasive imaging technique in determining HER2 expression levels, which could potentially improve cancer diagnosis and treatment planning.
At a glance
- Study Type
- Phase II clinical trial
- Drug
- Gallium (68Ga) Tezatabep Matraxetan ([68Ga]Ga-ABY-025)
- Administration
- Intravenous injection, max 220 MBq daily, 440 MBq total
- Target Conditions
- Gastro-esophageal cancer with HER2-expression, HER2-low breast cancer
- Main Objective
- Evaluate HER2 status in lesions using PET/CT imaging
- Key Secondary Objectives
- Define optimal parameters for HER2 status, investigate heterogeneity, assess safety
- Eligibility
- Adults (≥18 years) with metastatic disease, specific cancer types, and other health criteria
- Potential Benefits
- Non-invasive HER2 status assessment, improved diagnosis and treatment planning
What is GALLIUM (68GA) TEZATABEP MATRAXETAN?
GALLIUM (68GA) TEZATABEP MATRAXETAN, also known as [68Ga]Ga-ABY-025, is an innovative imaging agent used in a special type of scan called PET/CT (Positron Emission Tomography/Computed Tomography). This substance is not a treatment itself but a tool to help doctors better understand certain types of cancer.
Medical Conditions Targeted
This imaging agent is being studied for use in patients with specific types of cancer:
- Gastro-esophageal cancer with HER2-expression (cancer in the stomach or esophagus that has a specific protein called HER2)
- Breast cancer with low HER2-expression (also called 'HER2-low' breast cancer)
- Non-small cell lung cancer (NSCLC) that is HER2-positive
These cancers are characterized by the presence of a protein called HER2 (Human Epidermal growth factor Receptor 2) on the surface of cancer cells. The amount of HER2 can vary, which is why some cancers are described as "HER2-positive" or "HER2-low".
How It Works
GALLIUM (68GA) TEZATABEP MATRAXETAN works by attaching itself to HER2 proteins on cancer cells. The gallium-68 in the compound is radioactive, which allows it to be detected by a PET scanner. When injected into a patient, it circulates in the body and collects in areas where there are HER2-positive cancer cells. This allows doctors to:
- See where cancer cells are located in the body
- Determine how much HER2 protein is present in different tumors
- Potentially detect cancer that might not be visible with standard imaging techniques
Administration and Dosage
GALLIUM (68GA) TEZATABEP MATRAXETAN is given as an intravenous injection (directly into a vein). The maximum daily dose is 220 MBq (megabecquerels, a unit of radioactivity), with a maximum total dose of 440 MBq over a 2-day period. It's important to note that this is not a frequent treatment; it's typically administered only for imaging purposes.
Clinical Trial Objectives
The main goal of the clinical trial is to evaluate how well [68Ga]Ga-ABY-025 PET/CT can determine HER2 status in tumors. Some key objectives include:
- Comparing the HER2 status determined by the PET scan to traditional biopsy methods
- Investigating whether the scan can detect differences in HER2 levels within the same patient's different tumor sites
- Evaluating if the scan can detect tumors with low levels of HER2
- Assessing the safety of the procedure
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria. Some key inclusion criteria are:
- Age 18 or older
- Diagnosed with metastatic gastroesophageal adenocarcinoma, non-small cell lung cancer, or HER2-low breast cancer
- Have at least one tumor larger than 10 mm that can be biopsied
- Have a life expectancy of more than 12 weeks
There are also several exclusion criteria, such as significantly impaired kidney function, allergies to certain contrast media, and other health conditions that might interfere with the study or put the patient at risk.
Safety Considerations
As with any medical procedure, there are potential risks and side effects. The clinical trial is closely monitoring for any adverse events. Patients with certain heart conditions, uncontrolled high blood pressure, or inadequate organ function may not be eligible for the study due to safety concerns.
Potential Benefits
While GALLIUM (68GA) TEZATABEP MATRAXETAN is not a treatment itself, its use in imaging could potentially lead to several benefits:
- More accurate detection of HER2-positive tumors
- Better understanding of how HER2 levels might change during treatment
- Improved ability to monitor response to HER2-targeted therapies
- Potential to detect cancer spread (metastases) that might not be visible with standard imaging
It's important to note that this imaging agent is still under investigation, and more research is needed to fully understand its benefits and potential risks.